DavidM.PeereboomMD

Neuro-Oncology

Professor of Medicine, Cleveland Clinic College of Medicine; Director, Clinical Research, Brain Tumor and Neuro-Oncology Center

Join to view full profile

Dr. Peereboom is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Peereboom's full profile

Already have an account?

Office
9500 Euclid Ave
# R35
Cleveland, OH 44195
Phone+1 216-445-6068

Fax+1 216-444-9464

Summary

Dr. David Peereboom is a medical oncologist in the Burkhardt Brain Tumor Center at the Cleveland Clinic. He received his medical degree from Virginia Commonwealth University School of Medicine, completed his internal medicine residency at Case Western Reserve University and his fellowhip in medical oncology at the Johns Hopkins Oncology Center. He specializes in in neuro-oncology with expertise in primary and metastatic CNS malignancies including primary CNS lymphoma.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1990 - 1993
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1986 - 1989
Virginia Commonwealth University School of MedicineClass of 1986
Massachusetts Institute of TechnologyBS, Chemical Engineering, 1978 - 1982

Certifications & Licensure

OH State Medical License 1989 - 2026
MI State Medical License 2002 - 2018
NY State Medical License 2002 - 2010
IL State Medical License 2002 - 2005
PA State Medical License 2002 - 2004
MD State Medical License 1990 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America�s Best Doctors 2017
Cleveland�s Top Doctors 2015
America's Top Doctors Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2011, 2013
Fellow American College of Physicians, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
U.S. News Top Doctors 2011
Northern Ohio Live Castle Connolly, 2009
F. Merlin Bumpus Junior Investigator Award
Join now to see all

Clinical Trials

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas Start of enrollment: 2002 Oct 01
Completed
Phase 1, Phase 2
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Oct 01
Completed
Phase 2
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Start of enrollment: 2005 Aug 01
Completed
Phase 2
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Start of enrollment: 2007 Jan 01
Completed
Phase 2
Epothilone B in Treating Patients With CNS Metastases From Breast Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 2
Chemotherapeutic Agents in Brain/Breast Start of enrollment: 2008 Sep 01
Completed
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases Start of enrollment: 2009 Apr 01
Terminated
Phase 2
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2013 Aug 19
Active, not recruiting
Phase 1
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma Start of enrollment: 2016 Oct 11
Active, not recruiting
Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma Start of enrollment: 2016 Apr 08
Recruiting
Phase 1, Phase 2
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Start of enrollment: 2019 May 15
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2020 Jun 08
Terminated
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Start of enrollment: 2016 Jul 12
Terminated
Phase 2
Roles: Principal Investigator, Contact
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2023 Jul 24
Recruiting
Phase 1
Roles: Contact
Methimazole in Patients With Progressive Glioblastoma Start of enrollment: 2023 Jan 30
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Intraocular rituximab.
A D Singh, D M Peereboom
Eye. 2007-12-01
85 citations
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu
Nature Medicine. 2023-06-01
58 citations
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Tyler Y. Kang, Tony Jin, Heinrich Elinzano, David M. Peereboom
Journal of Neuro-Oncology. 2008-04-26

Journal Articles

Adjuvant chemotherapy in patients with newly diagnosed non-co-deleted anaplastic gliomas�a new standard
Braun KL, Peereboom DM, Translational Cancer Research, 1/1/2018
Phase 2 trial of SL-701 in relapsed/refractory glioblastoma: Preliminary correlation of immune response with longer-term survival
Peereboom DM, Nabors B, Kumthekar P, Badruddoja M, Fink K, Lieberman F, Phuphanich S, Dunbar E, Walbert T, Schiff D, Sherman J, Tran D, Ashby L, Butowski N, Iwamoto F,..., J Clin Oncol, 1/1/2018
Adjuvant chemotherapy in patients with newly diagnosed non-co-deleted anaplastic gliomas�a new standard
Braun KL, Peereboom DM, Transl Cancer Res, 1/1/2018
Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update
Aly Z, Peereboom DM, Curr Treat Options Neurol, 1/1/2016
NRG/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from Her2-positive breast cancer: A co...
Peereboom DM, Moughan J, Kim IA, De Los Santos JF, Sperduto PW, White JR, Mehta MP, Neuro Oncol, 1/1/2016
Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine + bevacizumab in patients with recurrent glioblastoma
Peereboom DM, Lathia JD, Sinyuk M, Ahluwalia MS, Brewer CJ, Vogelbaum MA., Neuro Oncol, 1/1/2016
The Cleveland Clinic experience with primary central nervous system lymphoma
Xie H, Ahluwalia MS, Peereboom DM., Am J Clin Oncol, 1/1/2015
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicen...
Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM., J Neurooncol, 1/1/2015
RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancer�A collabo...
Peereboom DM, Winter KA, Kim IA, De Los Santos JF, Sperduto PW, White JR, Mehta MP, J Clin Oncol, 1/1/2014
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA, Neuro Oncol, 1/1/2013
Clinical trial design in brain metastasis: Approaches for a unique patient population
Peereboom DM, Curr Oncol Rep., 1/1/2012
Phase I study of terameprocol in patients with recurrent high-grade glioma
Grossman SA, Ye X, Peereboom DM, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S; for the Adult Brain Tumor Consortium, Baltimore, MD, Neuro Oncol, 1/1/2012
Clinical trial design in brain metastasis: approaches for a unique patient population
Peereboom DM., Curr Oncol Rep, 1/1/2012
Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma
Xie H, Peereboom DM, J Clin Oncol, 1/1/2012
A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma
Peereboom DM, Rich JN, Supko JG, Lamborn K, Ye X, Sloan AE, Prados M, Grossman SA, Adult Brain Tumor Consortium (ABTC)., Neuro-Oncol, 1/1/2012
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery (SRS) in patients with 1-3 newly diagnosed brain metastases
Peereboom DM, Chao ST, Suh JH, Wang D, Mikkelsen T, Brewer CJ, Smolenski KN, Parsons MW, Elson P, Angelov L, Barnett GH, Vogelbaum MA, Weil RJ, J Clin Oncol, 1/1/2012
Capecitabine entry into brain metastases in women with breast cancer
Peereboom DM, Seidman AD, Tabar V, Weil RJ, Thorsheim HR, Smith QR, Lockman PR, Steeg PS., Neuro-Oncol, 1/1/2012
Ogilvie Syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma
Xie H, Peereboom DM, J Clin Oncol, 1/1/2012
A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma
Peereboom DM, Rich JN, Supko JG, Lamborn K, Ye X, Sloan AE, Prados M, Grossman SA, Adult Brain Tumor Consortium (ABTC)., J Clin Oncol, 1/1/2011
Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution
Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST, J Neurosurg, 1/1/2011
Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases
Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST., Neuro Oncol, 1/1/2011
Role of tyrosine kinase inhibitors in the management of high-grade gliomas
Ahluwalia MS, Patel M, Peereboom DM, Expert Rev Anticancer Ther, 1/1/2011
Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas
Ahluwalia MS, Patton C, Stevens G, Tekautz T, Angelov L, Vogelbaum MA, Weil RJ, Chao S, Elson P, Suh JH, Barnett GH, Peereboom DM., J Neurooncol, 1/1/2011
Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases
Peereboom DM, Brewer CJ, Suh JH, Chao ST, Parsons P, Elson G, Vogelbaum MA, Sade B, Barnett GH., Neuro-Oncol, 1/1/2010
Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases
Peereboom DM, Brewer C, Suh JH, Chao ST, Rini BI, Parsons P, Elson G, Barnett GH., Proc Am Soc Clin Oncol, 1/1/2010
Join now to see all

Books/Book Chapters

Glioblastoma
Chapter: Lessons Learned: Clinical Trials and other Interventions for Glioblastoma.
Page 279.0 - 290.0Bernatowicz R, Peereboom DMEditors: Brem S, Abdullah KG.Elsevier, Inc, Atlanta2017
Glioblastoma
Chapter: Lessons Learned: Clinical Trials and other Interventions for Glioblastoma
Page 279.0 - 290.0Bernatowicz R, Peereboom DM.Editors: Brem S, Abdullah KG.Elsevier, Inc, Atlanta2017
DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology
Chapter: Metastatic Cancer to the Brain
Page 1832. - 1844.Suh JH, Chao ST, Peereboom DM, Barnett, GHEditors: DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA.Lippincott Williams & Wilkins, PhiladelphiaEdition 10th,2015
Clinical Ophthalmic Oncology. Retinal Tumors
Chapter: Primary central nervous system and retinal lymphoma
Page 75.0 - 90.0Ahluwalia MS, Dahiya S, Aronow ME, Peereboom DM, Singh AD.Editors: Singh AD, Damato B.Springer, HeidelbergEdition 2nd,2014
Retina
Chapter: Primary vitreoretinal lymphoma.
Page 2373. - 2378.Turell ME, Schachat AP, Peereboom DM, Singh AD.Editors: Ryan SJ.Saunders/Elsevier, LondonEdition 5th,2013
Diagnosis and Treatment, Current Clinical Oncology Series
Chapter: Chemotherapy for High-Grade Gliomas.
Page 267.0 - 282.0Ahluwalia M, Peereboom DEditors: GH Barnett.Humana Press, Totowa, NJ2007
Clinical Ophthalmic Oncology
Chapter: Lymphoma of the retina and CNS.
Page 372.0 - 377.0Singh AD, Lewis H, Schachat AP, Peereboom DM.Editors: Singh AD, Damato BE, Pe'er J, Murphree AL, Perry JD.Sunders-Elsevier, Philadelphia2007
Diagnosis and Treatment, Current Clinical Oncology Series
Chapter: Chemotherapy for High-Grade Gliomas
Page 267.0 - 282.0Ahluwalia MS, Peereboom DEditors: Barnett GH.Humana Press, Totowa, NJ2006
Office Urology: The Clinician's Guide
Chapter: Prostate Cancer: Endocrine Therapy
Page 291.0 - 301.0Daw HA, Peereboom DMEditors: Kursh ED, Ulchaker JC.Humana Press, Totowa, NJ2001
Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management
Chapter: Paraneoplastic Syndromes.
Page 135.0 - 145.0Aldaabil R, Peereboom DM.Editors: Bukowski RM, Novick A.Humana Press, Totowa, NJ2000
Regional Chemotherapy: Clinical Research and Practice
Chapter: Principles of Intrathecal Chemotherapy
Page 305.0 - 317.0Stevens GH, Peereboom DMEditors: Markman M.Humana Press, Totowa, NJ2000
Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management
Chapter: Paraneoplastic Syndromes
Page 135.0 - 145.0Aldaabil R, Peereboom DM.Editors: Bukowski RM, Novick A.Humana Press, Totowa, NJ2000
Medicine for the Practicing Physician
Chapter: Essential Thrombocytosis.
Page 858.0 - 859.0Peereboom DM.Editors: Hurst JW.Appleton and Lange, Simon and Schuster, StamfordEdition 4th,1996
Medicine for the Practicing Physician
Chapter: Polycythemia Vera.
Page 862.0 - 865.0Peereboom DM.Editors: Hurst JW.Appleton and Lange, Simon and Schuster, StamfordEdition 4th,1996
Medicine for the Practicing Physician
Chapter: Idiopathic Myelofibrosis
Page 869.0 - 871.0Peereboom DMEditors: Hurst JW.Appleton and Lange, Simon and Schuster, StamfordEdition 4th,1996
Biology of Renal Cell Carcinoma
Chapter: Cytokine therapy of metastatic renal cell carcinoma: The Cleveland Clinic experience
Page 189.0 - 203.0Bukowski RM, Olencki T, Peereboom D, Budd GT, Murthy S, Tubbs R, Rayman P, McLain D, Klein E, Tuason L, Finke J.Editors: Bukowski RM, Finke JH, Klein EA.Springer-Verlag, New York1995
Join now to see all

Abstracts/Posters

Circulating Endothelial Cells in Recurrent Glioblastoma.
Stockham A, Borden E, Peereboom DM., Society for Neuro-Oncology Meeting, Orange County, CA, 1/1/2011
Ogilvie�s syndrome during chemotherapy of primary central nervous system lymphoma
Xie H, Peereboom DM., The American College of Physician National Meeting, San Diego, CA, 1/1/2011
Primary central nervous system lymphoma: the Cleveland Clinic experience
Xie H, Peereboom DM., Lepow Research Day, Case Western Reserve University, Cleveland, OH, 1/1/2011
Quality of life analysis for clinical trial of temozolomide in patients with anaplastic oligodendrogliomas
Hashemi-Sadraei, N, Brewer C, Schiff D, Fisher P, Chamberlain M, Pannullo S, Snodgrass S, Newton H, Elson P, Prayson R, Staugaitis S, Stevens G, Toms S, Vogelbaum M, B..., Proc Am Soc Clin Oncol, American Society for Clinical Oncology meeting, Chicago IL, 1/1/2010
Phase II trial of patupilone in patients with breast cancer brain metastases.
Kang T, Brewer C, Jin T, Conlin A, Seidman A, Peereboom D., Society of Neuro-Oncology Meeting, Dallas, TX, 1/1/2007
Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience
Kang TY, Jin T, Elinzano H, Peereboom D., Proc Am Soc Clin Oncol, American Society for Clinical Oncology meeting, Chicago IL, 1/1/2007
Phase II multicenter study of 7/7 dosing of temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma.
Kaur H, Wood L, Schiff D, Barnett G, Vogelbaum M, Stevens G, Prayson R, Staugaitis S, Elson P, Peereboom D., Proc Am Soc Clin Oncol, American Society for Clinical Oncology meeting, Chicago IL, 1/1/2003
Join now to see all

Lectures

Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Chemotherapy in Neuro-Oncology: Principles and Practice
New Orleans, LA - 1/1/2018
Systemic Therapy for Meningiomas
Santa Monica, CA - 1/1/2018
Update in Neuro-Oncology
Cleveland, OH - 1/1/2018
Munich, Germany - 1/1/2018
CNS Metastases Oral Abstracts
New Orleans, LA - 1/1/2018
Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine + bevacizumab in patients with recurrent glioblastoma
New Orleans, LA - 1/1/2018
Chemotherapy Principles and Practice in Neuro-Oncology
1/1/2017
Central Nervous System Tumors
1/1/2017
Highlights of the Day � CNS Malignancies
Chicago, IL - 1/1/2017
Perspective on Treating Patients with Newly Diagnosed Primary CNS Lymphoma
Skamania, WA - 1/1/2017
Current Therapeutic Approaches and Theoretical Paradigms in CNS Metastases: What is the Role of the Neurovascular Bundle?
Skamania, WA - 1/1/2017
Chemotherapy in Brain Metastases: Strategies for Treatment, Prevention and Progress
Skamania, WA - 1/1/2017
Update on Brain Metastases
Skamania, WA - 1/1/2017
Use of Bevacizumab in Brain Tumors
Skamania, WA - 1/1/2017
Update on Brain Metastases from Breast and Lung Cancer
Skamania, WA - 1/1/2017
The Impact of the Neurovascular Unit in CNS Metastases
Skamania, WA - 1/1/2017
Chemotherapy for Breast Cancer Brain Metastases
Skamania, WA - 1/1/2017
Primary and Metastatic Brain Tumors: Is More Treatment Better than Less?
Skamania, WA - 1/1/2017
Principles of Chemotherapy and Emerging Treatments in Breast Cancer Brain Metastases
Las Vegas, NV - 1/1/2016
Primary CNS Lymphoma
1/1/2016
Immunotherapy
1/1/2016
Vestibular Schwannomas: Early Observation and Systemic Management
Las Vegas, NV - 1/1/2015
Brain Metastasis: Management in 2015
1/1/2015
Systemic Therapy for Tumors of the Skull Base
Las Vegas, NV - 1/1/2014
Join now to see all

Other

Audio cast �Update in Brain Tumors�
Research to Practice
Cleveland, OH - 1/1/2010
Malignant Glioma Update Think Tank
Research to Practice
Miami, FL - 1/1/2009
Current Clinical Research Data on Bevacizumab in High Grade Gliomas
Research to Practice
Miami, FL - 1/1/2009
Human Epidermal Growth Factor Receptor-Family Education Network Curriculum
Development/Review 2003-2004, Teaching Slide Set Development, Genentech
New York, NY - 1/1/2004
Teaching Slide Set Development
Schering Plough
Dallas, TX - 1/1/2004
�Spinal Cord Compression� Video in-service
Hematology/Oncology Nursing Unit, Cleveland Clinic Foundation
Cleveland, OH - 1/1/2003
Join now to see all

Authored Content

First-in-Human Evaluation of the Cleveland Multiport Catheter for Convection-Enhanced Delivery of Topotecan in Recurrent High-Grade Glioma: Results of Pilot Trial 1 RelatedApril 2018
First-in-Human Evaluation of the Cleveland Multiport Catheter for Convection-Enhanced Delivery of Topotecan in Recurrent High-Grade Glioma: Results of Pilot Trial 1 RelatedApril 2018

Press Mentions

Electricity Helps Control Man’s Brain TumorAugust 7th, 2019
Living with Rare Brain Cancer: Woman Shares Story on Glioblastoma Awareness DayJuly 17th, 2019
ASCO 2018 – Saturday, June 2June 2nd, 2017
Join now to see all